Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

623 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.
McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, Bringhen S, Musto P, Anderson KC, Caillot D, Gay F, Moreau P, Marit G, Jung SH, Yu Z, Winograd B, Knight RD, Palumbo A, Attal M. McCarthy PL, et al. Among authors: musto p. J Clin Oncol. 2017 Oct 10;35(29):3279-3289. doi: 10.1200/JCO.2017.72.6679. Epub 2017 Jul 25. J Clin Oncol. 2017. PMID: 28742454 Free PMC article.
Conventional induction treatments do not influence overall survival in multiple myeloma.
Boccadoro M, Palumbo A, Argentino C, Dominietto A, Frieri R, Avvisati G, Comotti B, Lauta VM, Liberati M, Marmont F, Musto P, Tribalto M, Pileri A. Boccadoro M, et al. Among authors: musto p. Br J Haematol. 1997 Feb;96(2):333-7. doi: 10.1046/j.1365-2141.1997.d01-2041.x. Br J Haematol. 1997. PMID: 9029022 Free article.
An analysis of which subgroups of multiple myeloma patients, divided according to b(2)-microglobulin and plasma cell labeling index, benefit from high dose vs conventional chemotherapy.
Boccadoro M, Tarella C, Palumbo A, Argentino C, Triolo S, Dominietto A, Callea V, Lauta VM, Molica S, Musto P, Marmont F, Gianni AM, Pileri A. Boccadoro M, et al. Among authors: musto p. Haematologica. 1999 Oct;84(10):905-10. Haematologica. 1999. PMID: 10509038 Clinical Trial.
Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial.
Palumbo A, Bringhen S, Petrucci MT, Musto P, Rossini F, Nunzi M, Lauta VM, Bergonzi C, Barbui A, Caravita T, Capaldi A, Pregno P, Guglielmelli T, Grasso M, Callea V, Bertola A, Cavallo F, Falco P, Rus C, Massaia M, Mandelli F, Carella AM, Pogliani E, Liberati AM, Dammacco F, Ciccone G, Boccadoro M. Palumbo A, et al. Among authors: musto p. Blood. 2004 Nov 15;104(10):3052-7. doi: 10.1182/blood-2004-02-0408. Epub 2004 Jul 20. Blood. 2004. PMID: 15265788 Free article. Clinical Trial.
Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide.
Musto P, Falcone A, Sanpaolo G, Guglielmelli T, Zambello R, Balleari E, Catalano L, Spriano M, Cavallo F, La Sala A, Mantuano S, Nobile M, Melillo L, Scalzulli PR, Dell'Olio M, Bodenizza C, Greco MM, Carella AM Jr, Merla E, Carella AM, Boccadoro M, Cascavilla N, Palumbo A. Musto P, et al. Leuk Res. 2006 Mar;30(3):283-5. doi: 10.1016/j.leukres.2005.06.027. Epub 2005 Aug 18. Leuk Res. 2006. PMID: 16111749 Free article. Clinical Trial.
623 results